Page 129 - Eceptor News Today

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

Researchers from Indiana University School of Medicine are studying why neuropsychiatric symptoms, such as apathy and irritability, appear in most Alzheimer's disease patients before the onset of memory loss.

A plant virus that infects legumes, called cowpea mosaic virus, has a special power that you may not have known about: when injected into a tumor, it triggers the immune system to treat the cancer-;even metastatic cancer-;and prevents it from recurring.

A team of US-based scientists has recently demonstrated the cryo-electron microscopic structure and antigenicity of the attachment glycoprotein of the Nipah virus.

Cigarette smoke has been shown to deleteriously affect human health. For example, degenerative disc diseases are increasingly linked to cigarette smoking.

Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

If you're wondering why after two vaccination doses and a booster shot, you still got sick from the omicron strain of the virus that causes COVID-19, one possible answer may have been found in a recent study by researchers at Johns Hopkins Medicine and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.